No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
XNCR240816P22500
- 4.60
- 0.000.00%
15min DelayNot Open Jul 19 15:50 ET
0.00High0.00Low
0.00Open4.60Pre Close0 Volume1 Open Interest22.50Strike Price0.00Turnover120.77%IV6.48%PremiumAug 16, 2024Expiry Date3.36Intrinsic Value100Multiplier25DDays to Expiry1.24Extrinsic Value100Contract SizeAmericanOptions Type-0.6321Delta0.0619Gamma4.16Leverage Ratio-0.0433Theta-0.0100Rho-2.63Eff Leverage0.0191Vega
Intraday
- 5D
- Daily
No Data
News
Form 144 | Xencor(XNCR.US) Officer Proposes to Sell 665.51K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 9, $Xencor(XNCR.US)$ Officer Desjarlais John R intends to sell 36,329 shares of its common stock on Jul 9, with a total market value of approximately $665.51K. Source:
Xencor Insiders Sold US$891k Of Shares Suggesting Hesitancy
Xencor, Inc. (NASDAQ:XNCR) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When analyzing insider transactions, it is usually more valuable to
Xencor (NASDAQ:XNCR) Shareholders Have Endured a 52% Loss From Investing in the Stock Five Years Ago
Peeling Back The Layers: Exploring Xencor Through Analyst Insights
In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings, showcasing the evolvi
Express News | Raymond James Maintains Strong Buy on Xencor, Lowers Price Target to $40
Xencor Is Maintained at Outperform by RBC Capital
Xencor Is Maintained at Outperform by RBC Capital
Comments
Bassil Dahiyat's recent sale of Xencor shares is the largest insider sale in the past year. It's discouraging when insiders sell below the current price, suggesting satisfaction with a lower valuation. Despite insider ownership, caution is advised due to sales history.
Don't Ignore The Insider Selling In XencorXencor's share price rise doesn't match its P/S ratio, likely due to weaker forecast growth than the industry. These conditions may continue to limit the share price.
Xencor's lack of profitability and uninspiring revenue growth, despite its pursuit of growth, may have led to its share price decline. Investors may question its long-term viability with continued weak revenue growth and unprofitability.
$Pfizer(PFE.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
24
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2 ...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2 ...
37
6
Read more